Mutual funds may soon face some tough questions from market regulator Sebi regarding the exercise of their vote on key business proposals of the companies in whose shares they have put in investors’ money. The market watchdog is irked by the casual approach adopted by most of the funds when it comes to voting on proposals put forth by the company management for shareholder approval, as also the disclosure of these votes, a senior official told PTI.
Major public sector banks, including State Bank of India, Punjab National Bank and Bank of Baroda, are likely to soon raise lending rates making home, auto and commercial loans expensive. As many as a dozen banks, including private sector leader ICICI Bank have already hiked their lending rate by 25 basis points in response to the tightening of monetary policy by the Reserve Bank of India (RBI) last month.
Social networking site Facebook is planning to launch a video chat function next week for its millions of users in association with Skype, says a report. Facebook will launch a new video chat product, powered by Skype, that works in browser, technology blog TechCrunch said citing a source.
UNITED BIOTECH PVT. LTD. Versus ORCHID CHEMICALS AND PHARMACEUTICALS LTD. AND ORS (Delhi HC) – The Petitioner UBPL states that it is, inter alia, engaged in the manufacturing and selling of pharmaceutical preparations including injections bearing the trade mark FORZID. UBPL claims that since 2002 it took steps to launch CEFTAZIDIME injections in the market under the trade mark FORZID. It entered into a licence agreement with M/s. Oscar Remedies Pvt. Ltd. („ORPL‟), Haryana for manufacturing FORZID injections. UBPL made an application for registration of the said trade mark under No. 1144258 dated 18th October 2002 in Class 5. The said mark was advertised in Journal Mega dated 25th November 2003. The registration was granted unopposed. The sales figures of UBPL‟s products under the trade mark FORZID for the years 2002-03 till 2006-07 have been set out in the writ petition.
